ProMab Biotechnologies Custom Chimeric Antigen Receptor Cell Engineering: A complete service, from antigen to clinically relevant solution.
At ProMab Biotechnologies, we perform real-time cytotoxicity assays (RTCA), both with hematological cancers and solid tumor cell lines. The RTCA system we use incorporates a microelectronic biosensor system which continuously measures the impedance caused by adherent cells between the electrodes. An increase in the number of cells leads to an increase in impedance. In contrast, killing of the adherent target cells by CAR-T cells causes a decrease in impedance.
We also measure target cell-induced cytokine production by the CAR-T cells, either by ELISA or high-throughput cytokine screening. Cytokine release is a critical metric when validating CAR-T cells since a number of adverse reactions in patients is directly related to an extreme level of cytokines secreted from the CAR-T cells.
Below is an overview of the RTCA equipment and assay.